Bicalutamide
Loading...Bicalutamide Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Bicalutamide tablets, USP 50 mg daily are indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate.
Bicalutamide tablets, USP 150 mg daily are not approved for use alone or with other treatments [see Clinical Studies (14.2)].
History
There is currently no drug history available for this drug.
Other Information
Bicalutamide tablets contain 50 mg of bicalutamide USP, a non-steroidal androgen receptor inhibitor with no other known endocrine activity. The chemical name is propanamide, N [4 cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,(+-). The structural and molecular formulas are: 
Bicalutamide has a molecular weight of 430.37. The pKa’ is approximately 12. Bicalutamide is a fine white to off white powder which is practically insoluble in water at 37°C (5 mg per 1000 mL), slightly soluble in chloroform and absolute ethanol, sparingly soluble in methanol, and soluble in acetone and tetrahydrofuran.
Bicalutamide tablet is a racemate with its antiandrogenic activity being almost exclusively exhibited by the R-enantiomer of bicalutamide; the S-enantiomer is essentially inactive.
The inactive ingredients of bicalutamide tablets are lactose monohydrate, sodium starch glycolate type A, povidone, magnesium stearate, hypromellose, polyethylene glycol, and titanium dioxide.
Sources
Bicalutamide Manufacturers
-
Sun Pharma Global Fze
![Bicalutamide Tablet, Film Coated [Sun Pharma Global Fze]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Bicalutamide | Sun Pharma Global Fze
The recommended dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
2.1. Dosage Adjustment in Renal ImpairmentNo dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)].
2.2. Dosage Adjustment in Hepatic ImpairmentNo dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
-
Golden State Medical Supply, Inc.
Bicalutamide | Golden State Medical Supply, Inc.
The recommended dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
2.1. Dosage Adjustment in Renal ImpairmentNo dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)].
2.2. Dosage Adjustment in Hepatic ImpairmentNo dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
-
Dava Pharmaceuticals, Inc.
Bicalutamide | Dava Pharmaceuticals, Inc.
The recommended dose for Bicalutamide Tablets, USP therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that Bicalutamide Tablets, USP be taken at the same time each day. Treatment with Bicalutamide Tablets, USP should be started at the same time as treatment with an LHRH analog.
2.1. Dosage Adjustment in Renal ImpairmentNo dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)].
2.2. Dosage Adjustment in Hepatic ImpairmentNo dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
-
Major Pharmaceuticals
Bicalutamide | Major Pharmaceuticals
The recommended dose for bicalutamide therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide should be started at the same time as treatment with an LHRH analog.
2.1. Dosage Adjustment in Renal ImpairmentNo dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)].
2.2. Dosage Adjustment in Hepatic ImpairmentNo dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
-
Physicians Total Care, Inc.
Bicalutamide | Physicians Total Care, Inc.
The recommended dose for bicalutamide therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide should be started at the same time as treatment with an LHRH analog.
2.1 Dosage Adjustment in Renal ImpairmentNo dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)].
2.2 Dosage Adjustment in Hepatic ImpairmentNo dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n = 4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
-
Synthon Pharmaceuticals, Inc.
Bicalutamide | Synthon Pharmaceuticals, Inc.
The recommended dose for Bicalutamide Tablets, USP therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that Bicalutamide Tablets, USP be taken at the same time each day. Treatment with Bicalutamide Tablets, USP should be started at the same time as treatment with an LHRH analog.
2.1. Dosage Adjustment in Renal ImpairmentNo dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)].
2.2. Dosage Adjustment in Hepatic ImpairmentNo dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
-
Breckenridge Pharmaceutical, Inc.
Bicalutamide | Breckenridge Pharmaceutical, Inc.
The recommended dose for Bicalutamide Tablets, USP therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that Bicalutamide Tablets, USP be taken at the same time each day. Treatment with Bicalutamide Tablets, USP should be started at the same time as treatment with an LHRH analog.
2.1. Dosage Adjustment in Renal ImpairmentNo dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)].
2.2. Dosage Adjustment in Hepatic ImpairmentNo dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
-
Udl Laboratories, Inc.
Bicalutamide | Udl Laboratories, Inc.
The recommended dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
2.1 Dosage Adjustment in Renal ImpairmentNo dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)].
2.2 Dosage Adjustment in Hepatic ImpairmentNo dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n = 4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
-
American Health Packaging
Bicalutamide | American Health Packaging
The recommended dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
2.1 Dosage Adjustment in Renal ImpairmentNo dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)].
2.2 Dosage Adjustment in Hepatic ImpairmentNo dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
-
Northstar Rx Llc
Bicalutamide | Reckitt Benckiser Llc
shake bottle well before use measure only with dosing cup provided. Do not use dosing cup with other products. dose as follows or as directed by a doctor mL = milliliter adults and children 12 years of age and over 10 mL every 12 hours,
not to exceed 20 mL in 24 hours children 6 to under 12 years of age 5 mL every 12 hours,
not to exceed 10 mL in 24 hours children 4 to under 6 years of age 2.5 mL every 12 hours,
not to exceed 5 mL in 24 hours children under 4 years of age do not use -
Cadila Healthcare Limited
Bicalutamide | Cadila Healthcare Limited
The recommended dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
2.1 Dosage Adjustment in Renal ImpairmentNo dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)].
2.2 Dosage Adjustment in Hepatic ImpairmentNo dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
-
Accord Healthcare Inc
Bicalutamide | Johnson & Johnson Consumer Inc.
Clean the skin thoroughly before applying this product. Cover the entire affected area with a thin layer one to three times daily. Because excessive drying of the skin may occur, start with one application daily, then gradually increase to two or three times daily if needed or as directed by a doctor. If bothersome dryness or peeling occurs, reduce application to once a day or every other day. If going outside, apply sunscreen after using this product. If irritation or sensitivity develops, stop use of both products and ask a doctor. -
Teva Pharmaceuticals Usa Inc
Bicalutamide | Pd-rx Pharmaceuticals, Inc.
Dosage should be individualized for maximum beneficial effect. While the usual daily dosages given below will meet the needs of most patients, there will be some who may require higher doses. In such cases dosage should be increased cautiously to avoid adverse effects.
ADULTS: USUAL DAILY DOSE: Management of Anxiety Disorders and Relief
of Symptoms of Anxiety Depending upon severity of symptoms - 2mg
to 10 mg, 2 or 4 times daily Symptomatic Relief in Acute Alcohol
Withdrawal 10 mg, 3 or 4 times during the first 24 hours,
reducing to 5 mg, 3 or 4 times daily as needed Adjunctively for Relief of Skeletal Muscle
Spasm 2 mg to 10 mg, 3 or 4 times daily
Adjunctively in Convulsive Disorders 2 mg to 10 mg, 2 to 4 times daily Geriatric Patients, or in the presence of
debilitating disease 2 mg to 2.5 mg, 1 or 2 times daily initially;
increase gradually as needed and tolerated PEDIATRIC PATIENTS: Because of varied responses to CNS-acting
drugs, initiate therapy with lowest dose and
increase as required. Not for use in pediatric
patients under 6 months 1 mg to 2.5 mg, 3 or 4 times daily initially;
increase gradually as needed and tolerated
-
Golden State Medical Supply, Inc.
Bicalutamide | Golden State Medical Supply, Inc.
The recommended dose for Bicalutamide Tablets, USP therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that Bicalutamide Tablets, USP be taken at the same time each day. Treatment with Bicalutamide Tablets, USP should be started at the same time as treatment with an LHRH analog.
2.1. Dosage Adjustment in Renal ImpairmentNo dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)].
2.2. Dosage Adjustment in Hepatic ImpairmentNo dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
-
Apotex Corp.
Bicalutamide | Apotex Corp.
The recommended dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
2.1. Dosage Adjustment in Renal ImpairmentNo dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)].
2.2. Dosage Adjustment in Hepatic ImpairmentNo dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
-
Sandoz Inc
Bicalutamide | Sandoz Inc
2.1 Recommended Dose and ScheduleThe recommended dose for bicalutamide therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide be taken at the same time each day. Treatment with bicalutamide should be started at the same time as treatment with an LHRH analog. If a dose of bicalutamide is missed, take the next dose at the scheduled time. Do not take the missed dose and do not double the next dose.
2.2 Dosage Adjustment in Renal ImpairmentNo dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)].
2.3 Dosage Adjustment in Hepatic ImpairmentNo dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
-
American Health Packaging
Bicalutamide | Hyvee Inc
• take only as directed – see overdose warning • do not exceed 4 doses per 24 hrsadults & children 12 yrs & over
2 softgels with water every 6 hrs
children 4 to under 12 yrs
ask a doctor
children under 4 yrs
do not use
-
Remedyrepack Inc.
Bicalutamide | Remedyrepack Inc.
The recommended dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
No dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations(8.7)].
No dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
-
Sun Pharma Global Inc.
Bicalutamide | Sun Pharma Global Inc.
The recommended dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
2.1. Dosage Adjustment in Renal ImpairmentNo dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)].
2.2. Dosage Adjustment in Hepatic ImpairmentNo dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
-
Avkare, Inc.
Bicalutamide | Avkare, Inc.
The recommended dose for bicalutamide therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets USP be taken at the same time each day. Treatment with bicalutamide tablets USP should be started at the same time as treatment with an LHRH analog.
2.1 Dosage Adjustment in Renal ImpairmentNo dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)].
2.2 Dosage Adjustment in Hepatic ImpairmentNo dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n = 4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
-
Zydus Pharmaceuticals (Usa) Inc.
Bicalutamide | Zydus Pharmaceuticals (usa) Inc.
The recommended dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
2.1 Dosage Adjustment in Renal ImpairmentNo dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)].
2.2 Dosage Adjustment in Hepatic ImpairmentNo dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
-
Bryant Ranch Prepack
Bicalutamide | Bryant Ranch Prepack
The recommended dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
2.1. Dosage Adjustment in Renal ImpairmentNo dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations(8.7)].
2.2. Dosage Adjustment in Hepatic ImpairmentNo dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
-
Mylan Pharmaceuticals Inc
Bicalutamide | Mylan Pharmaceuticals Inc
2.1 Recommended Dose and ScheduleThe recommended dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog. If a dose of bicalutamide tablets is missed, take the next dose at the scheduled time. Do not take the missed dose and do not double the next dose.
2.2 Dosage Adjustment in Renal ImpairmentNo dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)].
2.3 Dosage Adjustment in Hepatic ImpairmentNo dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n = 4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].
![Bicalutamide Tablet, Film Coated [Golden State Medical Supply, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7c9a8877-7364-4a3c-9345-78279fa282eb&name=LabelGraphic-Bicalutamide50mg100s.jpg)
![Bicalutamide Tablet, Film Coated [Dava Pharmaceuticals, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=59df7b06-81d0-423c-9e80-9014d424b64c&name=bicalutamide-04.jpg)
![Bicalutamide Tablet [Major Pharmaceuticals]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=82d4877e-6ebf-4f75-a108-28dc840b07fc&name=82d4877e-6ebf-4f75-a108-28dc840b07fc-04.jpg)
![Bicalutamide Tablet, Film Coated [Physicians Total Care, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=020d34eb-9560-4218-9d87-dfdeff705c3a&name=packagelabel.jpg)
![Bicalutamide Tablet, Film Coated [Synthon Pharmaceuticals, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c267f783-1d39-4f27-83ed-8288577bf66d&name=bicalutamide-04.jpg)
![Bicalutamide Tablet, Film Coated [Breckenridge Pharmaceutical, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4db9bad7-6256-4473-ac48-9e56c4a24d51&name=bicalutamide-04.jpg)
![Bicalutamide Tablet, Film Coated [Udl Laboratories, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c563bba0-7f6b-46fe-898d-3965c97525eb&name=aca53fc1-506d-4a12-b74b-3f1c7362199c-04.jpg)
![Bicalutamide Tablet, Film Coated [American Health Packaging]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=93e7e9ae-901a-42bc-81c8-5f384675299f&name=acb15f19-762d-497b-9b01-38ff60c4314d-04.jpg)
![Bicalutamide Tablet, Film Coated [Northstar Rx Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=234e6a2c-a280-4a39-8777-9316e9d681fb&name=delsym-01.jpg)
![Bicalutamide Tablet, Film Coated [Cadila Healthcare Limited]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8e26fbf0-511c-44d9-b484-372d7b50b55e&name=bicalu-figure-04.jpg)
![Bicalutamide Tablet [Accord Healthcare Inc]](https://www.recallguide.org/wp-content/themes/bootstrap/assets/img/drug-image-placeholder.jpg)
![Bicalutamide Tablet, Film Coated [Teva Pharmaceuticals Usa Inc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c2768add-5e01-4ff4-afa3-230380d59a1f&name=55289092-1.jpg)
![Bicalutamide Tablet, Film Coated [Golden State Medical Supply, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=abaf380b-7434-426a-934b-73f6f094c82e&name=abaf380b-7434-426a-934b-73f6f094c82e-04.jpg)
![Bicalutamide Tablet [Apotex Corp.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7cd5fd99-ea7f-432d-aa05-8c0ab4fffb75&name=7cd5fd99-ea7f-432d-aa05-8c0ab4fffb75-04.jpg)
![Bicalutamide Tablet [Sandoz Inc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f32eadf6-d515-4307-a722-c49f0f1aef61&name=f6f05391-0639-4cf4-aacb-ed169cae6a8f-04.jpg)
![Bicalutamide Tablet [American Health Packaging]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aff579e2-7fb3-4407-b371-40d48317c695&name=c0696f92-61f9-4a3d-8b82-ed5bd025205d-01.jpg)
![Bicalutamide Tablet [Remedyrepack Inc. ]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=487ef40e-abb2-4107-b9e9-819e10c27321&name=MM4.jpg)
![Bicalutamide Tablet [Sun Pharma Global Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=427a872b-1b0b-41cf-aca2-49ce0163c7e6&name=bicalutamide-label.jpg)
![Bicalutamide (Bicalutamide) Tablet, Film Coated [Avkare, Inc.]](http://recallguide.cwdevelopsp.com/wp-content/themes/recallguide/assets/img/drug-image-placeholder.jpg)
![Bicalutamide Tablet, Film Coated [Zydus Pharmaceuticals (Usa) Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d0348cf0-f79a-4579-86c9-a5d25d688659&name=bicalutamidetable-figure-03.jpg)
![Bicalutamide Tablet [Bryant Ranch Prepack]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=175218a9-2795-4938-aeea-95750dc8b77c&name=53211.jpg)
![Bicalutamide Tablet, Film Coated [Mylan Pharmaceuticals Inc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0c3b8420-01ec-4a4a-97a2-222884522963&name=698743e4-5aa7-4ae8-b257-e133f6a58d77-04.jpg)
Login To Your Free Account